Why do we need drugs to treat the patient with obesity?

Obesity

Volumn 21, Issue 5, 2013, Pages 893-899

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; AMFEBUTAMONE; AMFEPRAMONE; AMINOREX; AMPHETAMINE; BENZPHETAMINE; CETILISTAT; EPHEDRA SINICA EXTRACT; EXENDIN 4; FLUOXETINE; LIRAGLUTIDE; LORCASERIN; MAZINDOL; METFORMIN; METHAMPHETAMINE; MONOAMINE DERIVATIVE; NALTREXONE; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PRAMLINTIDE; PRELU 2; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; THYROID HORMONE; TOPIRAMATE; UNCLASSIFIED DRUG;

BODY MASS; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; ENERGY BALANCE; EPIDEMIC; FAT MASS; FOOD AND DRUG ADMINISTRATION; HEALTH HAZARD; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE MODIFICATION; MONOTHERAPY; MORBIDITY; MORNING DOSAGE; MORTALITY; NONALCOHOLIC FATTY LIVER; NORADRENERGIC SYSTEM; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; PUBLIC HEALTH PROBLEM; REVIEW; RISK REDUCTION; TREATMENT DURATION; UNITED STATES; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; DRUG APPROVAL; HUMANS; OBESITY; WEIGHT LOSS;

EID: 84877825999     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20394     Document Type: Review

References (65)

1. Bray GA,. The Battle of the Bulge. Pittsburgh: Dorrance Publishing Co.; 2007.
2. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL,. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205-211.
3. Flegal KM, Carroll MD, Kit BK, Ogden CL,. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491.
4. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM,. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303: 242-249. Epub 2010 January 13.
5. Website: www.cdc.gov/nchs/databrief/db82 accessed Sept 8, 2012.
6. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
7. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-The evidence report. Obes Res 1998; 6: 51S-63S.
8. Bray GA,. A Guide to Obesity and the Metabolic Syndrome. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2011.
9. Putnam J, Allshouse J, Kantor LS,. U.S. per capita food supply trends: more calories, refined carbohydrates and fats. Food Rev 2002; 25: 2-15.
10. Swinburn B, Sacks G, Ravussin E,. Increased food energy supply is more than sufficient to explain the US epidemic of obesity. Am J Clin Nutr. 2009; 90: 1453-1456.
11. McLaren L,. Social and economic determinants of obesity. In:, Bray GA, and, Bouchard C, eds. Handbook of Obesity, Vol. 1, Epidemiology, Etiology, and Physiopathology. 3rd ed. New York: Informa Press 2013, in press.
12. Church TS, Thomas DM, Tudor-Locke C, et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One 2011; 6: e19657. Epub 2011 May 25.
13. Bray GA,. Obesity is a chronic, relapsing neurochemical disease. Int J Obes 2004; 28: 34-38.
14. Allison DB, Downey M, Atkinson RL, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring) 2008; 16: 1161-1177.
15. Catenacci VA, Wyatt HR,. America on the move. Med Clin North Am 2007; 91: 1079-1089.
16. Stuart RB, Davis B,. Slim Chance in a Fat World: Behavioral Control of Obesity. Champaign, IL: Research Press Company; 1972.
17. Wadden TA, Victoria LW, Moran CH, Bailer BA,. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation 2012; 125: 1157-1170.
18. Moyer VA,. Screening for and management of obesity in adults: U.S. Preventive Services Task Force Recommendation. Ann Intern Med 2012; 157: 373-378.
19. Flemyng M,. A Discourse on the Nature, Causes, and Cure of Corpulency. Illustrated by a Remarkable Case. Read before the Royal Society November 1757. London: L Davis and C Reymers; 1760.
20. Bray GA,. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-2589.
21. Lancet Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096. Epub 2009 Mar 18.
22. Whitlock G, Huxley, R,. Obesity and mortality rates. In: In:, Bray GA, and, Bouchard C, eds. Handbook of Obesity, Vol. 1, Epidemiology, Etiology, and Physiopathology. 3rd ed. New York: Informa Press 2013; in press.
23. Puhl RM, Brownell KD,. Psychosocial origins of obesity stigma: toward changing a powerful and pervasive bias. Obes Rev 2003; 4: 213-227.
24. Hoppé R, Ogden J,. Practice nurses' beliefs about obesity and weight related interventions in primary care. Int J Obes Relat Metab Disord 1997; 21: 141-146.
25. Schwartz MB, Chambliss HO, Brownell KD, Blair SN, Billington C,. Weight bias among health professionals specializing in obesity. Obes Res 2003; 11: 1033-1039.
26. Maiman LA, Wang VL, Becker MH, Finlay J, Simonson M,. Attitudes toward obesity and the obese among professionals. J Am Diet Assoc 1979; 74: 331-336.
27. Finkelstein EA, Ruhm CJ, Kosa KM,. Economic causes and consequences of obesity. Annu Rev Public Health 2005; 26: 239-257.
28. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-761.
29. Sjostrom L, Narbro K, Sjostrom CD, et al. Swedish obese subjects study. Effect of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-772.
30. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367: 695-704.
31. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1577-1585.
32. Knowler WC, Barrett-Connor E, Fowler SE, -et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
33. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.
34. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease (CVD) risk factors in individuals with type 2 diabetes: one year results of Look AHEAD Trial. Diabetes Care 2007; 30: 1374-1383.
35. Look AHEAD Research Group, Wing RR,. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575.
36. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program Randomized Trial. Ann Intern Med 2005; 142: 611-619.
37. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
38. Sjostrom CD, Lissner L, Sjostrom L, et al. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects. Obes Res 1997; 5: 519-530.
39. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65.
40. Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med 2012; 366: 1209-1217.
41. Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 2009; 32: 1017-1019.
42. Aronne LJ, Wadden T, Isoldi KK, Woodworth KA,. When prevention fails: obesity treatment strategies. Am J Med 2009; 122 (4 Suppl 1): S24-S32.
43. LeBlanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T,. Effectiveness of primary care-relevant treatments for obesity in adults. A systematic evidence of review for the U.S. Preventive Task Force. Ann Intern Med 2011; 155: 434-447.
44. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256.
45. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352. Epub 2011 Apr 8
46. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
47. Goldstein DJ,. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415.
48. Blackburn GL,. Benefits of weight loss in the treatment of obesity. Am J Clin Nutr 1999; 69: 347-349.
49. Douketis JC, Macie C, thabane L, Williamson DF,. Systematic review of long-term weight loss studies in obese adults: clinical significant and applicability to clinical practice. Int J Obes 2005; 29: 1153-1167.
50. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29: 2102-2107.
51. Phelan S, Kanaya AM, Subak LL, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol 2012; 187: 939-944.
52. Sarwer DB, Wadden TA, Moore RH, Eisenberg MH, Raper SE, Williams NN,. Changes in quality of life and body image after gastric bypass surgery. Surg Obes Relat Dis 2010; 6: 608-614.
53. Williamson DA, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K,. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med 2009; 169: 163-171.
54. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363 (10): 905-917.
55. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-530. doi: 10.1111/j.1463-1326. 2011.01554.x. Epub 2012 Jan 18.
56. Rissanen A, Lean M, Rossner S, Segal K, Sjostrom L,. Predictive values of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003; 27: 103-109.
57. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet. Early response to treatment predicts weight maintenance. Diabetes Obes Metab 2006; 7: 699-708.
58. Finer N, Ryan DH, Renz CL, Hewkin AC,. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006; 8: 206-213.
59. Wadden TA, Neiberg RH, Wing RR, et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) 2011; 19: 1987-1998.
60. Jakicic JM, Tate DF, Lang W, et al. Effect of a stepped-care intervention approach on weight loss in adults: a randomized clinical trial. JAMA 2012; 307: 2617-2626.
61. Colman E,. Food and drug administration's obesity drug guidance document: a short history. Circulation 2012; 125: 2156-2164.
62. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M,. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-273.
63. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL,. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: 1-11.
64. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
65. Bray GA,. Evaluation of drugs for treating obesity. Obes Res 1995; 3 (Suppl 4): 425S-434S.